

Table I. Studies of first-line CHOP or CHOP-like chemotherapy in adult PTLD

	Number of patients who received CHOP-like therapy	Front-line therapy for PTLD before CHOP-like therapy	Chemotherapy	Response	Therapy-associated mortality
Garrett <i>et al</i> , 1993 (1)	4 (retrospective)	Immune suppression reduction or withdrawal	CHOP	4 CR	Sepsis: 1 Liver failure: 1
Mamzer-Bruneel <i>et al</i> , 2000 (2)	10 (retrospective)	Immune suppression reduction or withdrawal (<i>n</i> = 9), anti B-cell monoclonal antibodies (<i>n</i> = 1)	CHOP +/- surgical resection	6 CR 3 PR	Sepsis: 5
Norin <i>et al</i> , 2004 (3)	12 (retrospective)	Immune suppression reduction or withdrawal (<i>n</i> = 12), antiviral therapy (<i>n</i> = 9), rituximab (<i>n</i> = 1)	CHOP	5 CR	Sepsis: 2 Liver failure: 1
Buell <i>et al</i> , 2005 (4)	90 (retrospective)	Immune suppression reduction or withdrawal in 55% of all patients; no other front-line therapy mentioned	CHOP No data on further therapies	No data on response rates or therapy-associated mortality 1, 3, 5-year OS of 57%, 36% and 24%	
Elstrom <i>et al</i> , 2006 (5)	23 (retrospective)	Immune suppression reduction or withdrawal (<i>n</i> = 23), radiation before or after chemotherapy (<i>n</i> = 7), rituximab (<i>n</i> = 7)	CHOP +/- radiation (10 patients) R-CHOP +/- radiation (9 patients) Other chemotherapy +/- radiation (4 patients)	13 CR 4 PR	Cardiotoxicity: 1 Rejection: 1 Infections: 4
Fohrer <i>et al</i> , 2006 (6)	24 (prospective)	Immune suppression reduction (<i>n</i> = 24), rituximab (<i>n</i> = 8)	ACVBP (20 patients) + cranial radiation (2 patients[#]) + high-dose methotrexate (1 patient[#]) + rituximab (1 patient)	22 CR 2 PR 5 and 10-year actuarial OS of 60% and 55%	Infections: 3
Taylor <i>et al</i> , 2006 (7)	13 (retrospective)	None (reduction in immunosuppression parallel to chemotherapy)	CHOP (2 patients) R-CHOP (4 patients) PMitCEBO (4 patients) Other chemotherapy* (3 patients)	9 CR 1 and 5-year DFS of 69% and 62%	None

CR: complete remission; PR: partial remission; OS: overall survival, R-CHOP: rituximab + CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone); ACVBP: doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone; # patients with initial cerebral involvement; PMitCEBO: prednisolone, mitoxantrone, cyclophosphamide, etoposide, bleomycin, vincristine; *: PACEBOM (prednisone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine, methotrexate), ChIVPP PABIOE (doxorubicin, bleomycin, vincristine, etoposide alternating with chlorambucil, vinblastine, procarbazine, prednisone), CHOD/BVAM (cyclophosphamide, doxorubicin, bcnu, vincristine, methotrexate, cytosine arabinoside)